Related Experiment Videos
Effects of calcitonin therapy in deafness associated with Paget's disease of bone
British Medical Journal
|October 26, 1974
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Care of Women With Preterm Prelabour Rupture of the Membranes Prior to 24+0 Weeks of Gestation: Scientific Impact Paper No. 76.
BJOG : an international journal of obstetrics and gynaecology·2025
A mechanical task for measuring sign- and goal-tracking in humans: A proof-of-concept study.
Behavioural brain research·2022
Climate change adaptation in conflict-affected countries: A systematic assessment of evidence.
Discover sustainability·2022
Radiation-related toxicities and outcomes in endometrial cancer: are obese women at a disadvantage?
International journal of clinical oncology·2017
Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026